UK – NICE recommends Sobi’s Kineret for first-line use in Still’s disease

The National Institute for Health and Care Excellence (NICE) has recommended Sobi’s Kineret for the first-line treatment of the rare inflammatory disorder Still’s disease.

NICE has approved Kineret (anakinra) to treat systemic juvenile idiopathic arthritis (sJIA) in people aged eight months or over with a body weight of 10kg or more, who have not responded to at least one conventional disease modifying antirheumatic drug (DMARD).

The biologic therapy is also recommended for use in patients with adult-onset Still’s disease (AOSD) who have responded inadequately to two or more conventional DMARDs…